{"created":"2023-05-15T14:38:21.951606+00:00","id":49516,"links":{},"metadata":{"_buckets":{"deposit":"91f5fca0-40f7-4026-8bfc-894297927017"},"_deposit":{"created_by":1,"id":"49516","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"49516"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00049516","sets":["1"]},"author_link":["797101","797098","797091","797093","797100","797109","797113","797095","797099","797110","797088","797097","797103","797105","797107","797096","797112","797094","797108","797102","797114","797104","797092","797089","797090","797111","797087","797106"],"item_8_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2019-01","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"81","bibliographicPageStart":"76","bibliographicVolumeNumber":"10","bibliographic_titles":[{"bibliographic_title":"Oncotarget"}]}]},"item_8_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"The aims of this study were to clarify the safety and efficacy of 12-fraction carbon-ion radiotherapy (CIRT) for primary renal cell carcinoma (RCC) and to confirm the recommended dose in a prospective clinical trial.\nThis clinical trial was planned as a non-randomized, open-label, single-center phase I/II study of CIRT monotherapy. The incidence of acute adverse events was the primary endpoint. Dose-limiting toxicities (DLTs) were defined as grade ≥3 skin, gastrointestinal tract, or urologic adverse events.\nBased on the eligibility criteria, 8 patients with primary RCC, including 3 medically inoperable patients and 5 patients with tumors >4 cm, were enrolled. Of the 8 patients, 5 were treated with 66 Gy (relative biological effectiveness [RBE]), and subsequently, the dose was escalated to 72 Gy (RBE) for the remaining 3 patients. The median follow-up time was 43.1 months. No DLTs were observed at any dose level though the end of follow-up. Although 1 patient died of pneumonia 3 months after CIRT, which was determined to be unrelated to CIRT, no grade 3 or higher adverse events were observed, and both local control and cancer-specific survival rates were 100%.\nIn conclusion, the safety and efficacy of CIRT hypofractionation using 12-fractions for the treatment of eligible RCC patients, including those with inoperable or tumor size >4 cm, were confirmed in this prospective trial, and a recommended dose of 72 Gy (RBE) was established.","subitem_description_type":"Abstract"}]},"item_8_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Inpact Journals"}]},"item_8_relation_14":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"10.18632/oncotarget.26539","subitem_relation_type_select":"DOI"}}]},"item_8_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1949-2553","subitem_source_identifier_type":"ISSN"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Kasuya, Goro"}],"nameIdentifiers":[{"nameIdentifier":"797087","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Tsuji, Hiroshi"}],"nameIdentifiers":[{"nameIdentifier":"797088","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Nomiya, Takuma"}],"nameIdentifiers":[{"nameIdentifier":"797089","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Makishima, Hirokazu"}],"nameIdentifiers":[{"nameIdentifier":"797090","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Haruyama, Yasuo"}],"nameIdentifiers":[{"nameIdentifier":"797091","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kobashi, Gen"}],"nameIdentifiers":[{"nameIdentifier":"797092","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Hayashi, Kazuhiko"}],"nameIdentifiers":[{"nameIdentifier":"797093","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Ebner, Daniel"}],"nameIdentifiers":[{"nameIdentifier":"797094","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Omatsu, Tokuhiko"}],"nameIdentifiers":[{"nameIdentifier":"797095","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kishimoto, Riwa"}],"nameIdentifiers":[{"nameIdentifier":"797096","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Yasuda, Shigeo"}],"nameIdentifiers":[{"nameIdentifier":"797097","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Igarashi, Tatsuo"}],"nameIdentifiers":[{"nameIdentifier":"797098","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Oya, Mototsugu"}],"nameIdentifiers":[{"nameIdentifier":"797099","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Akakura, Koichiro"}],"nameIdentifiers":[{"nameIdentifier":"797100","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Suzuki, Hiroyoshi"}],"nameIdentifiers":[{"nameIdentifier":"797101","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Ichikawa, Tomohiko"}],"nameIdentifiers":[{"nameIdentifier":"797102","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Shimazaki, Jun"}],"nameIdentifiers":[{"nameIdentifier":"797103","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kamada, Tadashi"}],"nameIdentifiers":[{"nameIdentifier":"797104","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Group for Genitourinary Tumors, Working"}],"nameIdentifiers":[{"nameIdentifier":"797105","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kasuya, Goro","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"797106","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Tsuji, Hiroshi","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"797107","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Nomiya, Takuma","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"797108","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Makishima, Hirokazu","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"797109","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Ebner, Daniel","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"797110","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Omatsu, Tokuhiko","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"797111","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kishimoto, Riwa","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"797112","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Yasuda, Shigeo","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"797113","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kamada, Tadashi","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"797114","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Prospective clinical trial of 12-fraction carbon-ion radiotherapy for primary renal cell carcinoma","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Prospective clinical trial of 12-fraction carbon-ion radiotherapy for primary renal cell carcinoma"}]},"item_type_id":"8","owner":"1","path":["1"],"pubdate":{"attribute_name":"公開日","attribute_value":"2018-12-28"},"publish_date":"2018-12-28","publish_status":"0","recid":"49516","relation_version_is_last":true,"title":["Prospective clinical trial of 12-fraction carbon-ion radiotherapy for primary renal cell carcinoma"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T23:53:46.047764+00:00"}